JP Morgan Maintains Overweight on RAPT Therapeutics, Lowers Price Target to $32
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Anupam Rama has maintained an Overweight rating on RAPT Therapeutics (NASDAQ:RAPT) but lowered the price target from $39 to $32.
August 16, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan has maintained an Overweight rating on RAPT Therapeutics but lowered the price target from $39 to $32.
The news is directly related to RAPT Therapeutics. While the Overweight rating is positive, the lowering of the price target might have a neutral to slightly negative impact on the stock in the short term. However, the overall impact is hard to predict without additional information.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100